While the company achieved 12.37% year-over-year revenue growth, the core business model is constrained by a thin 13.92% gross margin and a concerning -41.85% net margin.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Sales/Revenue | 342.56M | 304.85M | 245.22M | 215.38M |
| Revenue Growth % | 12.37% | 24.32% | 13.85% | - |
| Cost of Goods Sold | 294.86M | 266.13M | 190.36M | 162.88M |
| COGS % of Revenue | 86.08% | 87.3% | 77.63% | 75.62% |
| Gross Profit | 47.69M | 38.72M | 54.86M | 52.51M |
| Gross Margin % | 13.92% | 12.7% | 22.37% | 24.38% |
| Gross Profit Growth % | 23.17% | -29.42% | 4.48% | - |
| Operating Expenses | 73.49M | 60.97M | 58.46M | 132.18M |
| OpEx % of Revenue | 21.45% | 20% | 23.84% | 61.37% |
| Selling, General & Admin | 68.24M | 55.99M | 54.87M | 102.95M |
| SG&A % of Revenue | 19.92% | 18.37% | 22.38% | 47.8% |
| Research & Development | 3M | 3.37M | 3.59M | 4.28M |
| R&D % of Revenue | 0.88% | 1.11% | 1.46% | 1.99% |
| Other Operating Expenses | 2.24M | 1.61M | 0 | 24.94M |
| Operating Income | -25.79M | -22.25M | -3.59M | -79.67M |
| Operating Margin % | -7.53% | -7.3% | -1.47% | -36.99% |
| Operating Income Growth % | -15.92% | -519.01% | 95.49% | - |
| EBITDA | -25.66M | -22.14M | -3.81M | -58.35M |
| EBITDA Margin % | -7.49% | -7.26% | -1.55% | -27.09% |
| EBITDA Growth % | -15.9% | -481.22% | 93.47% | - |
| D&A (Non-Cash Add-back) | 134.51K | 112.09K | 0 | 21.32M |
| EBIT | -24.4M | -23.1M | -3.81M | -79.89M |
| Net Interest Income | -12.96M | -13.85M | -16.02M | -16.29M |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 12.96M | 13.85M | 16.02M | 16.29M |
| Other Income/Expense | -11.57M | -14.7M | -16.24M | -16.51M |
| Pretax Income | -37.37M | -36.95M | -19.83M | -96.18M |
| Pretax Margin % | -10.91% | -12.12% | -8.09% | -44.66% |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -143.36M | -145.39M | -125.51M | -188.4M |
| Net Margin % | -41.85% | -47.69% | -51.18% | -87.47% |
| Net Income Growth % | 1.4% | -15.84% | 33.38% | - |
| Net Income (Continuing) | -37.37M | -36.95M | -19.83M | -96.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 168.69M | 158.64M | 76.66M | 71.66M |
| EPS (Diluted) | -21.78 | -22.14 | -19.08 | -28.62 |
| EPS Growth % | 1.63% | -16.04% | 33.33% | - |
| EPS (Basic) | -21.78 | -22.14 | -19.08 | -28.62 |
| Diluted Shares Outstanding | 6.58M | 6.58M | 6.58M | 6.58M |
| Basic Shares Outstanding | 6.58M | 6.58M | 6.58M | 6.58M |
| Dividend Payout Ratio | - | - | - | - |
Liquidity and regulatory exposure
As reported in recent financial disclosures, POM achieved a 12.37% year-over-year revenue growth, suggesting that the company is successfully capturing market share within the chronic care segment despite the intense competitive environment characterized by larger, ecosystem-backed digital health platforms operating within the Chinese domestic market.
The double-digit growth indicates that the company's focus on high-frequency chronic disease management is resonating with its target patient base. However, investors should monitor whether this expansion is driven by sustainable recurring prescription refills or lower-margin bulk transactional volume, as the latter would imply limited long-term durability.
Based on the company's reported figures, POM maintains a gross margin of 13.92%, which appears to reflect a business model heavily reliant on low-margin pharmaceutical distribution rather than high-margin medical services, leaving the firm with limited pricing power against larger e-commerce aggregators in the sector.
This thin margin profile suggests that the company's 'Internet Hospital' integration has yet to achieve the scale necessary to shift the revenue mix toward more profitable service-based fees. The current cost structure appears highly sensitive to centralized procurement policies, which may continue to compress margins if government price caps on chronic medications persist.
According to the latest financial statements, POM reported a net margin of -41.85%, a figure that warrants further investigation as it suggests that non-operating expenses or excessive administrative overhead are significantly eroding the value generated by the company's core pharmaceutical e-commerce and online medical service operations.
The substantial gap between the operating margin of -7.53% and the net margin indicates that the company is burdened by significant non-operating drags, potentially including interest costs or one-time valuation adjustments. This level of bottom-line deterioration raises questions regarding the sustainability of the current customer acquisition strategy.
As indicated by the reported cash and equivalents of only $7.65 million against an annual revenue base of $342 million, the company's financial position appears highly vulnerable, suggesting that the current burn rate may necessitate imminent and potentially dilutive external financing to maintain ongoing operations.
Short-sellers would likely focus on this precarious liquidity situation, as the company lacks the capital buffer typically required to navigate regulatory shocks or unexpected shifts in the Chinese healthcare landscape. The disconnect between the firm's 'tech-platform' branding and its distressed retail-like financial profile suggests that the market may be mispricing the company's long-term viability.
Quick answers to the most common questions about buying POM stock.
For fiscal year 2024, POMDOCTOR Ltd (POM) reported total revenue of $342.6M. This represents a 59.0% increase compared to $215.4M in 2021.
POMDOCTOR Ltd (POM) reported a net loss of $143.4M for the fiscal year ending 2024.
POMDOCTOR Ltd (POM) reported an operating income of $-25.8M, resulting in an operating profit margin of -7.5%. This margin reflects the operational efficiency of the business before interest and taxes.
POMDOCTOR Ltd (POM) generated $47.7M in gross profit for the year, representing a gross profit margin of 13.9%. This demonstrates the company's core pricing power and production efficiency.